Daniel Castellano

机构：Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre · ORCID：0000-0002-9106-0687

发表论文 741 篇 · 总被引 42443 次 · h-index 74

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 123)
• Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer (2025 · Annals of Oncology · 被引 38)
• BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes (2025 · Annals of Oncology · 被引 21)
• EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). (2025 · Journal of Clinical Oncology · 被引 5)
• Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107) (2026 · Journal of Clinical Oncology · 被引 3)
• Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial (2025 · European Urology Oncology · 被引 2)